MMAE

(redirected from Monomethyl Auristatin E)
AcronymDefinition
MMAEMonomethyl Auristatin E
MMAEMechanical, Materials and Aerospace Engineering
MMAEMultiple Model Adaptive Estimation (Bayesian technique using Kalman filters)
MMAEMultiple Model Adaptive Estimator
MMAEMethod of Matched Asymptotic Expansions
MMAEMoses Montefiore Anshe Emunah (Baltimore, MD)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Abbreviations ASCT: Autologous stem cell transplant CTA: Computed tomography angiogram MMAE: Monomethyl auristatin E. http://dx.doi.org/10.1155/2016/2359437
According to the company, ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilising its proprietary technology.
Adcetris, an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology.
Ladiratuzumab vedotin is an investigational antibody-drug conjugate designed to deliver a potent and clinically validated cell-killing agent, monomethyl auristatin E, to cancer cells which express the protein LIV-1.
Tisotumab vedotin is an investigational antibody-drug conjugate designed to target Tissue Factor antigen on cancer cells and deliver the cell-killing agent monomethyl auristatin E directly inside cancer cells.
Tisotumab vedotin is an investigational antibody-drug conjugate, or ADC, designed to target Tissue Factor antigen on cancer cells and deliver the cell-killing agent monomethyl auristatin E, or MMAE, directly inside cancer cells.
Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of Genmab's human antibody that binds to Tissue Factor (TF) and Seattle Genetics' ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).